We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cellular Dynamics International, Inc. (‘CDI’), a recently acquired business arm of FUJIFILM Holdings Corporation (FUJIY - Free Report) , launched a new venture, ‘Opsis Therapeutics’. The move is in sync with Fujifilm’s aim to underpin regenerative medicine business over time.
Formed on Jul 31, 2016, Opsis Therapeutics would be focusing on inventing and developing medicines to restore vision to patients suffering from variable retinal diseases. The venture is in partnership with David Gamm, M.D., Ph.D. and is aimed at developing novel cell therapeutic programs. Gamm is a global leader and pioneer in the transplantation and differentiation of iPSC (induced pluripotent stem cell)-based retinal cells.
Cellular Dynamics has expertise in the creation and development of iPSC-derived cell therapeutics. In partnership with Opsis Therapeutics, CDI aims to expand its cGMP iPSC bank for reinforcing its therapeutics pipeline. This would aid in the creation of first-in-class cell therapies, required for the treatment of various retinal diseases.
Fujifilm Regenerative Medicine Business
Fujifilm offers diversified categories of products in the market. In order to sustain or boost market competency, premium technology companies, like Fujifilm, Photronics Inc. (PLAB - Free Report) , Xerox Corporation (XRX - Free Report) and Canon Inc. , undertake incessant efforts to solidify or widen their existing product portfolios.
In Mar 2015, Fujifilm acquired CDI for roughly $307 million. This investment was made by the company to fortify its regenerative medicine business. Cellular Dynamics has formed a Cooperative Research and Development Agreement with the U.S. National Eye Institute for developing medicines required for the treatment of retinal degenerative disease. We perceive that CDI’s new partnership venture will further strengthen its iPSC-derived cell therapeutics solutions’ expertise.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Fujifilm Cellular Dynamics Launches Opsis Therapeutics
Cellular Dynamics International, Inc. (‘CDI’), a recently acquired business arm of FUJIFILM Holdings Corporation (FUJIY - Free Report) , launched a new venture, ‘Opsis Therapeutics’. The move is in sync with Fujifilm’s aim to underpin regenerative medicine business over time.
Formed on Jul 31, 2016, Opsis Therapeutics would be focusing on inventing and developing medicines to restore vision to patients suffering from variable retinal diseases. The venture is in partnership with David Gamm, M.D., Ph.D. and is aimed at developing novel cell therapeutic programs. Gamm is a global leader and pioneer in the transplantation and differentiation of iPSC (induced pluripotent stem cell)-based retinal cells.
Cellular Dynamics has expertise in the creation and development of iPSC-derived cell therapeutics. In partnership with Opsis Therapeutics, CDI aims to expand its cGMP iPSC bank for reinforcing its therapeutics pipeline. This would aid in the creation of first-in-class cell therapies, required for the treatment of various retinal diseases.
Fujifilm Regenerative Medicine Business
Fujifilm offers diversified categories of products in the market. In order to sustain or boost market competency, premium technology companies, like Fujifilm, Photronics Inc. (PLAB - Free Report) , Xerox Corporation (XRX - Free Report) and Canon Inc. , undertake incessant efforts to solidify or widen their existing product portfolios.
In Mar 2015, Fujifilm acquired CDI for roughly $307 million. This investment was made by the company to fortify its regenerative medicine business. Cellular Dynamics has formed a Cooperative Research and Development Agreement with the U.S. National Eye Institute for developing medicines required for the treatment of retinal degenerative disease. We perceive that CDI’s new partnership venture will further strengthen its iPSC-derived cell therapeutics solutions’ expertise.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>